Skip to content

Management of nasotrancheal intubation complications

Effect of % 2 mupirocin intranasal ointment before and during nasotracheal intubation on decreasing its complications in oral and maxillofacial surgery

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016102122951N2
Enrollment
44
Registered
2016-12-18
Start date
2016-03-24
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endotracheal nasal tube bacterial load. Lung diseases due to external agents

Interventions

In the control group, this ointment not be used.
Intervention 1: 8 hours before and during nasoracheal intubation, nasal ointment of 2 % mupirocin will apply. Intervention 2: In the control group, this ointment not be used.
Prevention
8 hours before and during nasoracheal intubation, nasal ointment of 2 % mupirocin will apply.

Sponsors

Research deputy of Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: All patients who are going to have maxillofacial surgery and nasotracheal intubation; age from 20 to 60 years Exclusion criteria: contraindications of nasotracheal intubation; nasal polyps; Chronic sinusitis; upper airway infections; allergy to mupirocin; pregnancy and lactation.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Endotracheal nasal tube bacterial load. Timepoint: after surgery. Method of measurement: Microbial culture.;Nasal congestion. Timepoint: 0, 2, 4, 6, 12 hours After anesthesia. Method of measurement: questionnaire.;Facilitate breathing through the nose. Timepoint: 0, 2, 4, 6, 12 hours After anesthesia. Method of measurement: questionnaire.;Ease of extubation. Timepoint: After anesthesia. Method of measurement: check list.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDR. Monire Roshandel

Tabriz University of Medical Sciences

milad.ghanizadeh@gmail.com+98 41 3335 9680

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026